RUNX1 and acute lymphoblastic leukemia: This rearrangement is associated with a favorable clinical outcome under present treatment protocol, such as intensive chemotherapy or allogeneic hematopoietic cell transplantation [10], but up to 20% of ETV6-RUNX1-positive pediatric B-ALL patients have a recurrence and still succumb to their disease [11].